CA-GLOBALLOGIC-INC
23.11.2020 15:02:12 CET | Business Wire | Press release
GlobalLogic Inc. , a leader in Digital Product Engineering, today announced that it has acquired ECS Group , a leading digital transformation and DevOps consultancy. Headquartered in London, ECS delivers digital solutions that harness the latest cloud technologies, with a focus on Digital Engineering, Data Analytics and Customer Experience. The company serves multiple industries, with particular expertise in the banking and financial services sector.
With the acquisition of ECS, GlobalLogic advances its European strategy, expands its Financial Services footprint and adds a host of complementary cloud-centric offerings to its portfolio. ECS brings to GlobalLogic a highly regarded proficiency in cloud architecture and advisory services as well as expertise in leading cloud platforms. Notably, ECS possesses rich Amazon Web Services (AWS) capabilities, for which ECS is an Advanced Consulting Partner and Amazon Connect Service Delivery Partner. Additionally, ECS holds the DevOps Competency Accreditation from AWS.
“We’re always in search of differentiated companies that enhance our capabilities and expand our reach,” stated Shashank Samant , President and CEO, GlobalLogic. “ECS’s expertise in complex cloud services, its strong position and presence in the UK, and the company’s heritage in regulated industries such as financial services are all valuable additions to GlobalLogic. We are very excited to have the talented ECS team on board to deliver outstanding digital outcomes for our clients.”
Founded in 2008, ECS currently has more than 650 employees worldwide. Its core competence is to enable its clients to leverage cloud technologies and digital engineering to become more customer-centric, nimble and efficient. The company uses Agile methodologies and enterprise-grade DevOps techniques to rapidly deploy and scale teams working on critical client projects. While blue chip retail banks represent the foundation of ECS’s client base, the company also works with marquee customers in other industries such as telecommunications, pharmaceuticals and energy.
“The demand for digital engineering and cloud services continues to grow at an accelerated pace,” said Mark Farrington , Chief Executive Officer, ECS. “Joining GlobalLogic is a game-changer for ECS. With access to a broader set of competencies and global scale, we can address a wider range of client opportunities. With its people-oriented culture, GlobalLogic is a fantastic match for ECS at every level. We are excited to embark on this journey together.”
Terms of the transaction were not disclosed. Under the agreement, ECS will continue to operate with its existing leadership and staff as a wholly owned subsidiary of GlobalLogic.
Alantra acted as lead adviser to ECS, identified the clear strategic rationale for a deal with GlobalLogic, and played a key role managing the transaction process.
Useful GlobalLogic Links:
GlobalLogic: http://www.globallogic.com
LinkedIn: https://www.linkedin.com/company/globallogic/
Facebook: https://www.facebook.com/GlobalLogic/
Twitter: https://twitter.com/GlobalLogic
Useful ECS Links
ECS: https://ecs.co.uk/
LinkedIn: https://www.linkedin.com/company/ecsconsulting/
Facebook: https://www.facebook.com/ecsconsulting/
Twitter: https://twitter.com/ECS_IT
About ECS
ECS is a UK digital transformation consultancy business founded in 2008. Though specialized in regulatory compliance fields, the company helps clients in all industries transform their businesses using advanced custom IT solutions by providing Data & Analytics, Customer Experience, and Digital Engineering solutions. For clients seeking the use of turn-key products, ECS also implements proven cloud and data management platforms such as ServiceNow, Splunk, and Amazon Web Services. Through engineering excellence, the ECS team is committed to enabling clients with smart data-driven solutions that improve customer engagement and staff productivity.
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital product engineering. We help our clients design and build innovative products, platforms, and digital experiences for the modern world. By integrating strategic design, complex engineering, and vertical industry expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the communications, financial services, automotive, healthcare, technology, media and entertainment, manufacturing, and semiconductor industries.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005472/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom